#Exact Sciences Oncodetect Test Shows Promising Results in Colorectal Cancer Detection Amidst Share Performance Chall...

Exact Sciences releases data showing effectiveness of cancer test

Exact Sciences is touting new results for its Oncodetect cancer test, which demonstrate its “strong performance” in detecting disease and predicting recurrence.  That’s according to Brian Baranick, general manager of precision oncology at the Madison-based diagnostics company.  “We’re thrilled to...

Exact Sciences’ MRD Test Impresses in Late-Stage Colon Cancer

Results from a trial of Exact Science’s Oncodetect test at the 2025 American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI.) showed the company seems to be on track with its molecular residual disease (MRD) test. Exact’s test is designed to find any last remaining cells after colon cancer treatment. In the Alpha-CORRECT study, the Oncodetect test achieved a 78% sensitivity in post-surgical checks and a 91% sensitivity …

OGT Delivers Superior MRD Detection Capabilities with New SureSeq Myeloid MRD Panel

Today, OGT announces the North American launch of its new next-generation sequencing (NGS) SureSeq™ Myeloid MRD Panel, which provides a flexible NGS workflow for the detection of ultra-low frequency measurable residual disease (MRD)-associated biomarkers in acute myeloid leukemia (AML).

Colorectal cancer is one of the most common cancers globally, occurring in both men and women. According to data from GLOBOCAN 2022, colorectal cancer ranks third among the most common cancers in the world and second in cancer mortality. In Vietnam, nearly 17,000 new cases were recorded, ranking fourth in

Understanding the Concept of MRD for Patients With Cancer

Dr. Christopher Flowers discusses MRD testing in cancer care, why this is an important concept to understand and how it relates to recurrence in patients.

Exact Sciences post positive results from MRD trial

The US company said that results from the Alpha-CORRECT trial saw its colon cancer diagnostic Oncodetect achieving a sensitivity rate of 91%.